STOCK TITAN
  1. Home
  2. News
  3. BPMC

Blueprint Medicines Corp - BPMC STOCK NEWS

Welcome to our dedicated news page for Blueprint Medicines (Ticker: BPMC), a resource for investors and traders seeking the latest updates and insights on Blueprint Medicines.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Blueprint Medicines's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Blueprint Medicines's position in the market.

News
Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Blueprint Medicines Corporation (Nasdaq: BPMC) announced that CEO Kate Haviland will present a corporate overview and 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024. A live webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
conferences
-
News
Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis
Rhea-AI Summary
Blueprint Medicines Corporation (Nasdaq: BPMC) announced that the European Commission has approved AYVAKYT® (avapritinib) for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment. AYVAKYT is the first and only approved therapy for people living with ISM in Europe, designed to potently and selectively target KIT D816V, the primary underlying driver of the disease. The approval is based on data from the PIONEER trial, where AYVAKYT achieved significant improvements across a broad range of symptoms with a safety profile comparable to placebo. The majority of patients living with SM have ISM, and there are approximately 40,000 people living with ISM in the European Union.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.95%
Tags
none
-
News
Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting
Rhea-AI Summary
Blueprint Medicines Corporation (Nasdaq: BPMC) announced data from the HARBOR Part 1 trial of elenestinib in indolent systemic mastocytosis at the 65th American Society of Hematology Annual Meeting. Elenestinib demonstrated being well-tolerated, clinically active, and showed broad symptom improvement. The company continues to advance its scientific understanding and treatment of systemic mastocytosis to expand and extend its SM franchise leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Blueprint Medicines Corporation (BPMC) granted non-qualified stock options and restricted stock units (RSUs) to two new employees under its 2020 Inducement Plan. The options have an exercise price of $72.05 per share and will vest over time, subject to continued employment. The RSUs will also vest over time, subject to the same condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
none
-
News
Blueprint Medicines to Present at JMP Securities Hematology and Oncology Summit
Rhea-AI Summary
Blueprint Medicines Corporation (BPMC) to participate in fireside chat at JMP Securities Hematology and Oncology Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
conferences
-
News
Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis
Rhea-AI Summary
Blueprint Medicines Corporation (BPMC) announced that the European Medicines Agency has recommended the approval of AYVAKYT for the treatment of adult patients with indolent systemic mastocytosis (ISM) in the EU, potentially becoming the first and only therapy for this condition in Europe. The positive opinion was based on the PIONEER trial, where AYVAKYT showed significant improvements in symptoms and a comparable safety profile to placebo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.79%
Tags
none
News
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Blueprint Medicines Corporation has granted non-qualified stock options and restricted stock units (RSUs) to three new employees under its 2020 Inducement Plan. The options have an exercise price of $59.90 per share and will vest gradually over time, while the RSUs will vest annually. These grants are subject to the terms and conditions of the Inducement Plan and the stock option and RSU agreement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Blueprint Medicines Reports Third Quarter 2023 Results
Rhea-AI Summary
Blueprint Medicines reports 90% YoY growth in AYVAKIT net product revenues, achieving $54.2 million in Q3 2023. Plan to present data from Part 1 of the HARBOR trial of elenestinib at ASH 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.61%
Tags
earnings
-
News
Blueprint Medicines to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023
Rhea-AI Summary
Blueprint Medicines Corporation to report Q3 financial results and provide corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
conferences earnings
News
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Blueprint Medicines grants stock options and restricted stock units to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
none
Stock BPMC logo
Blueprint Medicines Corp

Nasdaq:BPMC

BPMC Rankings

#1130 Ranked by Market Cap
#1628 Ranked by Stock Gains
N/A Ranked by Dividends

BPMC Stock Data

5.27B
60.55M
0.85%
108.07%
7.14%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About BPMC

blueprint medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. we are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. by focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. we see a substantial opportunity in kinase drug discovery and development